Maria Goralski

Maria Goralski

Auto-generated profile, based on publicly available information

Maria Goralski

Department of Internal Medicine, Program in Molecular Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. K3.124, Dallas, TX 75390, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2017 in Science
Verified
Journal Article
Closed access
PDF file
THTing Han
Ting Han
MGMaria Goralski
Maria Goralski
NGNicholas Gaskill
Nicholas Gaskill
ECEmanuela Capota
Emanuela Capota
JKJiwoong Kim
Jiwoong Kim
DNDeepak Nijhawan
Deepak Nijhawan
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755

19 November 2021 in Science Advances
Verified
Journal Article
Open access
SSShivendra Vikram Singh
Shivendra Vikram Singh
WQWaise Quarni
Waise Quarni
MGMaria Goralski
Maria Goralski
SWShibiao Wan
Shibiao Wan
HJHongjian Jin
Hongjian Jin
JYJun Yang
Jun Yang
Degradation of RBM39 by indisulam leads to exceptional response in high-risk neuroblastoma.